BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 11482988)

  • 1. Toxicity assessment of intratumoral injection of the herpes simplex type I thymidine kinase gene delivered by retrovirus in patients with refractory cancer.
    Singh S; Cunningham C; Buchanan A; Jolly DJ; Nemunaitis J
    Mol Ther; 2001 Aug; 4(2):157-60. PubMed ID: 11482988
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Avoidance of bone marrow suppression using A-5021 as a nucleoside analog for retrovirus-mediated herpes simplex virus type I thymidine kinase gene therapy.
    Hasegawa Y; Nishiyama Y; Imaizumi K; Ono N; Kinoshita T; Hatano S; Saito H; Shimokata K
    Cancer Gene Ther; 2000 Apr; 7(4):557-62. PubMed ID: 10811473
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Herpes simplex virus type 1 thymidine kinase/ganciclovir (HSV(1)-TK/GCV) system as an effective "in vivo death switch" of live tumor vaccines].
    Kang Y; Xu CJ; Liu XS; Wu CQ; Zhong CP; Gu JR
    Ai Zheng; 2005 Aug; 24(8):909-14. PubMed ID: 16086864
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Studies on herpes simplex virus thymidine kinase gene and GCV system for treatment of human bladder carcinoma].
    He J; Chen Y; Li H; Lu Y; Yan Y; Tan X
    Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2004 Jun; 21(3):428-32. PubMed ID: 15250149
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In situ generation of pseudotyped retroviral progeny by adenovirus-mediated transduction of tumor cells enhances the killing effect of HSV-tk suicide gene therapy in vitro and in vivo.
    Okada T; Caplen NJ; Ramsey WJ; Onodera M; Shimazaki K; Nomoto T; Ajalli R; Wildner O; Morris J; Kume A; Hamada H; Blaese RM; Ozawa K
    J Gene Med; 2004 Mar; 6(3):288-99. PubMed ID: 15026990
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Suicide gene therapy of ovarian cancer: an experimental study in rats using retroviral-mediated transfer of herpes simplex virus thymidine kinase gene.
    Nagy HJ; Panis Y; Fabre M; Klatzmann D; Houssin D; Soubrane O
    Anticancer Res; 2000; 20(6B):4633-8. PubMed ID: 11205314
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum-resistant gene transfer to oral cancer cells by Metafectene and GeneJammer: application to HSV-tk/ganciclovir-mediated cytotoxicity.
    Konopka K; Fallah B; Monzon-Duller J; Overlid N; Düzgünes N
    Cell Mol Biol Lett; 2005; 10(3):455-70. PubMed ID: 16217556
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immune response induced by retrovirus-mediated HSV-tk/GCV pharmacogene therapy in patients with glioblastoma multiforme.
    Rainov NG; Kramm CM; Banning U; Riemann D; Holzhausen HJ; Heidecke V; Burger KJ; Burkert W; Körholz D
    Gene Ther; 2000 Nov; 7(21):1853-8. PubMed ID: 11110418
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of a HSV thymidine kinase stimulating substance, scopadulciol, in improving the efficacy of cancer gene therapy.
    Hayashi K; Lee JB; Maitani Y; Toyooka N; Nemoto H; Hayashi T
    J Gene Med; 2006 Aug; 8(8):1056-67. PubMed ID: 16779868
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gene therapy for endometrial carcinoma with the herpes simplex thymidine kinase gene.
    Ural AU; Takebe N; Adhikari D; Ercikan-Abali E; Banerjee D; Barakat R; Bertino JR
    Gynecol Oncol; 2000 Mar; 76(3):305-10. PubMed ID: 10684701
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I and biodistribution study of recombinant adenovirus vector-mediated herpes simplex virus thymidine kinase gene and ganciclovir administration in patients with head and neck cancer and other malignant tumors.
    Xu F; Li S; Li XL; Guo Y; Zou BY; Xu R; Liao H; Zhao HY; Zhang Y; Guan ZZ; Zhang L
    Cancer Gene Ther; 2009 Sep; 16(9):723-30. PubMed ID: 19363470
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antitumor effects on human melanoma xenografts of an amplicon vector transducing the herpes thymidine kinase gene followed by ganciclovir.
    Wang S; Qi J; Smith M; Link CJ
    Cancer Gene Ther; 2002 Jan; 9(1):1-8. PubMed ID: 11916238
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Local inflammation and devascularization--in vivo mechanisms of the "bystander effect" in VPC-mediated HSV-Tk/GCV gene therapy for human malignant glioma.
    Floeth FW; Shand N; Bojar H; Prisack HB; Felsberg J; Neuen-Jacob E; Aulich A; Burger KJ; Bock WJ; Weber F
    Cancer Gene Ther; 2001 Nov; 8(11):843-51. PubMed ID: 11773974
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characteristics of ovarian cancer cells transduced by the bicistronic retroviral vector containing GM-CSF and HSV-TK genes.
    Guan J; Ma L; Wei L
    Chin Med J (Engl); 2001 Feb; 114(2):147-51. PubMed ID: 11780195
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adenovirus-mediated gene transfer of enhanced Herpes simplex virus thymidine kinase mutants improves prodrug-mediated tumor cell killing.
    Wiewrodt R; Amin K; Kiefer M; Jovanovic VP; Kapoor V; Force S; Chang M; Lanuti M; Black ME; Kaiser LR; Albelda SM
    Cancer Gene Ther; 2003 May; 10(5):353-64. PubMed ID: 12719705
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I study of replication-competent adenovirus-mediated double suicide gene therapy for the treatment of locally recurrent prostate cancer.
    Freytag SO; Khil M; Stricker H; Peabody J; Menon M; DePeralta-Venturina M; Nafziger D; Pegg J; Paielli D; Brown S; Barton K; Lu M; Aguilar-Cordova E; Kim JH
    Cancer Res; 2002 Sep; 62(17):4968-76. PubMed ID: 12208748
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Purified herpes simplex virus thymidine kinase retroviral particles: III. Characterization of bystander killing mechanisms in transfected tumor cells.
    Burrows FJ; Gore M; Smiley WR; Kanemitsu MY; Jolly DJ; Read SB; Nicholas T; Kruse CA
    Cancer Gene Ther; 2002 Jan; 9(1):87-95. PubMed ID: 11916247
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Monocyte chemoattractant protein-1 gene delivery enhances antitumor effects of herpes simplex virus thymidine kinase/ganciclovir system in a model of colon cancer.
    Kagaya T; Nakamoto Y; Sakai Y; Tsuchiyama T; Yagita H; Mukaida N; Kaneko S
    Cancer Gene Ther; 2006 Apr; 13(4):357-66. PubMed ID: 16224495
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase I clinical trial of thymidine kinase-based gene therapy in advanced hepatocellular carcinoma.
    Sangro B; Mazzolini G; Ruiz M; Ruiz J; Quiroga J; Herrero I; Qian C; Benito A; Larrache J; Olagüe C; Boan J; Peñuelas I; Sádaba B; Prieto J
    Cancer Gene Ther; 2010 Dec; 17(12):837-43. PubMed ID: 20689572
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Non-small cell lung cancer as a target disease for herpes simplex type 1 thymidine kinase-ganciclovir gene therapy.
    Määttä AM; Tenhunen A; Pasanen T; Meriläinen O; Pellinen R; Mäkinen K; Alhava E; Wahlfors J
    Int J Oncol; 2004 Apr; 24(4):943-9. PubMed ID: 15010834
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.